Bide Pharmatech Future Growth
Future criteria checks 5/6
Bide Pharmatech is forecast to grow earnings and revenue by 31.1% and 21.3% per annum respectively. EPS is expected to grow by 31% per annum. Return on equity is forecast to be 10.2% in 3 years.
Key information
31.1%
Earnings growth rate
31.0%
EPS growth rate
Pharmaceuticals earnings growth | 17.9% |
Revenue growth rate | 21.3% |
Future return on equity | 10.2% |
Analyst coverage | Low |
Last updated | 14 Jun 2024 |
Recent future growth updates
No updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,899 | 210 | N/A | -41 | 1 |
12/31/2025 | 1,776 | 280 | N/A | 101 | 2 |
12/31/2024 | 1,288 | 211 | N/A | 139 | 1 |
3/31/2024 | 1,102 | 99 | -44 | 12 | N/A |
12/31/2023 | 1,092 | 110 | -118 | -57 | N/A |
9/30/2023 | 1,050 | 161 | -141 | -89 | N/A |
6/30/2023 | 988 | 171 | -65 | -23 | N/A |
3/31/2023 | 909 | 157 | 35 | 73 | N/A |
12/31/2022 | 834 | 146 | -9 | 30 | N/A |
9/30/2022 | 768 | 129 | -38 | -21 | N/A |
6/30/2022 | 707 | 114 | -45 | -28 | N/A |
3/31/2022 | 649 | 101 | -141 | -115 | N/A |
12/31/2021 | 606 | 98 | -94 | -65 | N/A |
12/31/2020 | 391 | 59 | -34 | 4 | N/A |
12/31/2019 | 249 | -1 | -2 | 3 | N/A |
12/31/2018 | 163 | -19 | -16 | -9 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688073's forecast earnings growth (31.1% per year) is above the savings rate (2.9%).
Earnings vs Market: 688073's earnings (31.1% per year) are forecast to grow faster than the CN market (22.3% per year).
High Growth Earnings: 688073's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 688073's revenue (21.3% per year) is forecast to grow faster than the CN market (13.7% per year).
High Growth Revenue: 688073's revenue (21.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688073's Return on Equity is forecast to be low in 3 years time (10.2%).